Revolution Medicines, Inc. RVMD
Nov 5, 2026, 2:36 PM EST
- YTD
- +131.36%
- 1 year
- +210.55%
- Market cap
- 39.44B
- EPS (ttm)
- -9.13
- Shares out
- 214.34M
- Forward P/E
- -34.65
- YTD return
- +131.36%
- 1-year return
- +210.55%
- Volume
- 5.00M
- Avg volume
- 1.93M
- Open
- 209.05
- Previous close
- 199.70
- Day's range
- 181.61 – 209.29
- 52-week range
- 59.34 – 221.15
- Beta
- 1.43
- Analysts
- Strong Buy
- Price target
- 258.84 (+40.5%)
- Earnings date
- Feb 24, 2027
30m -5.14 (-2.72%)
Key statistics
- Enterprise value
- 38.88B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 16.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -711.61M
- Total cash
- 3.94B
- Total debt
- 1.19B
- Return on equity
- -79.09%
- Short % of float
- 6.37%
- 50-day average
- 198.45
- 200-day average
- 156.73
Analyst view
Consensus: strong buy
- Target (low)
- 179.00
- Target (mean)
- 258.84
- Target (high)
- 320.00
- Strong buy5
- Buy19
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -2.38.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -1.90 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -2.35 | -1.90 | +0.45 | +19.15% |
| Aug 5, 2026 | Jun 30, 2026 | -2.04 | -3.06 | -1.02 | -50.00% |
| May 6, 2026 | Mar 31, 2026 | -1.84 | -2.29 | -0.45 | -24.46% |
| Feb 25, 2026 | Dec 31, 2025 | -1.58 | -1.86 | -0.28 | -17.72% |
| Nov 5, 2025 | Sep 30, 2025 | -1.42 | -1.61 | -0.19 | -13.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | TD Cowen | reit | Buy | Buy |
| Oct 19, 2026 | Truist Securities | main | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 15, 2026 | Needham | reit | Buy | Buy |
| Oct 14, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- revmed.com
News
Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $222 
Truist Securities Reiterates Buy on Revolution Medicines, Raises Price Target to $261 - Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $298
- Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $340
What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call 
What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call 
Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript 
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates 
Revolution Medicines Q3 2026 Earnings Call Transcript 
12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on RVMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERS JACK LEE | Chief Financial Officer | Sale | Jun 23, 2026 | 123,269 |
| BORISY ALEXIS | Director | Stock Award(Grant) | Jun 17, 2026 | 2,340,080 |
| GOLDSMITH MARK A | Chief Executive Officer | Sale | Aug 20, 2026 | 0 |
| HORN MARGARET A | Chief Operating Officer | Sale | Jun 16, 2026 | 154,647 |
| HORNING SANDRA | Director | Stock Award(Grant) | Jun 17, 2026 | 97,765 |
| KELSEY STEPHEN MICHAEL | Officer | Sale | Sep 10, 2026 | 291,876 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.39% | 13,695,790 | 2.74B | Jun 29, 2026 |
| Farallon Capital Management LLC | 6.32% | 13,550,796 | 2.71B | Jun 29, 2026 |
| FMR, LLC | 5.69% | 12,200,422 | 2.44B | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 5.34% | 11,443,357 | 2.29B | Jun 29, 2026 |
| Jupiter Topco LLC | 5.01% | 10,736,145 | 2.14B | Jun 29, 2026 |
| Darwin Global Management, Ltd. | 4.96% | 10,629,822 | 2.12B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 6,412,413 | 1.28B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 4,631,150 | 924.84M | Jun 29, 2026 |
| Growth Fund of America | 1.38% | 2,964,768 | 592.06M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.25% | 2,670,853 | 533.37M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.15% | 2,472,885 | 493.84M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.07% | 2,291,511 | 457.61M | Jun 29, 2026 |